Immunomedics
Biotech · Acquired
Trodelvy (sacituzumab govitecan), a Trop-2 targeted antibody-drug conjugate for triple-negative breast cancer and urothelial carcinoma
immunomedics.com →- Grants
- $15M
- 54 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 21 granted · 19 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓19831985198719891991199319951997199920012003200520072009201120132015
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Non-enzymatic Immunohistochemistry | $50,000 | |
| Federal grant | Department of Health and Human Services · N43 · Prepare Monoclonal Antibody Conjugates | $50,000 | |
| Federal grant | Department of Health and Human Services · N43 · Preparation Of Monoclonal Antibody Conjugates | $50,000 | |
| Federal grant | Department of Health and Human Services · N43 · Radioimmunodetection With Anti-csap Mab's | $50,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Siderophore Analogs In Radioimmunodetection Of Tumors | $50,000 | |
| Federal grant | Department of Health and Human Services · N44 · Monoclonal Antibody Conjugates For Therapy And Diagnosis | $250,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Production Of 188 Re-labeled Monoclonal Antibodies | $50,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Carcinoembryonal Antigen Idiotype Vaccine | $50,000 | |
| Federal grant | Department of Health and Human Services · Phase I · TC-99M-F(AB)2 Instant Kits For Radioimmunoscintigraphy | $50,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Humanized Antibody (MA5) For Breast Cancer Treatment | $49,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Engineering A Unique Conjugation Site On Ab Light Chain | $75,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Practical Re 186 Labeled Products For Radioimmunotherapy | $81,000 | |
| Federal grant· 1 of 3 same day | Department of Health and Human Services · Phase II · Cdr-grafted Antibody For Radioimmunotherapy Of Lymphoma | $353,318 | |
| Federal grant· 2 of 3 same day | Department of Health and Human Services · Phase I · Cdr Grafted Antibody For Radioimmunotherapy Of Lymphoma | $100,000 | |
| Federal grant· 3 of 3 same day | Department of Health and Human Services · Phase II · Cdr-grafted Antibody For Radioimmunotherapy Of Lymphoma | $396,682 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeted Drug Therapy Of Pneumocystis Carinii Infection | $100,000 | |
| Federal grant· 1 of 3 same day | Department of Health and Human Services · Phase II · Improved Radioiodination Methods For Radioimmunotherapy | $275,478 | |
| Federal grant· 2 of 3 same day | Department of Health and Human Services · Phase I · Improved Radioiodination Methods For Radioimmunotherapy | $100,000 | |
| Federal grant· 3 of 3 same day | Department of Health and Human Services · Phase II · Improved Radioiodination Methods For Radioimmunotherapy | $474,522 | |
| Federal grant | Department of Health and Human Services · Phase I · Imaging Of Breast Tumor Receptors With TECHNETIUM-99M | $100,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Improving Tumor Radioimmunotherapy By Pna Pretargeting | $100,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Positron Emission Tomography With Monoclonal Antibodies | $100,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Bacterial Expression Of Lymphoma Rnrnase Immunotoxin | $100,000 | |
| Federal grant· 1 of 3 same day | Department of Health and Human Services · Phase II · Radioimmunotherapy Using Bispecific Antibodies | $442,937 | |
| Federal grant· 2 of 3 same day | Department of Health and Human Services · Phase I · Two Step TC99M Imaging Using Bispecific Antibodies | $100,000 | |
| Federal grant· 3 of 3 same day | Department of Health and Human Services · Phase II · Radioimmunotherapy Using Bispecific Antibodies | $253,958 | |
| Federal grant | Department of Health and Human Services · Phase I · Pre-targeted GALLIUM-68 Positron Emission Tomography | $100,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Minimal-disease radioimmunotherapy of colorectal cancer | $100,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Molecular Imaging by Affinity Enhancement PET | $119,171 | |
| Federal grant | Department of Health and Human Services · Phase I · Tetravalent bispecific fusion antibody for immunotherapy | $134,285 | |
| Federal grant· 1 of 4 same day | Department of Health and Human Services · Phase II · An anti-CD74 MAb-drug conjugate for B-cell malignancies | $492,190 | |
| Federal grant· 2 of 4 same day | Department of Health and Human Services · Phase II · An anti-CD74 MAb-drug conjugate for B-cell malignancies | $309,824 | |
| Federal grant· 3 of 4 same day | Department of Health and Human Services · Phase I · An Anti-CD-74 MAb-drug Conjugate for B-Cell Malignancies | $134,285 | |
| Federal grant· 4 of 4 same day | Department of Health and Human Services · Phase I · F-18 FDG Peptides for Pretargeted PET Imaging of Pancrea | $134,285 | |
| Federal grant· 1 of 3 same day | Department of Health and Human Services · Phase II · Dock and Lock: Novel Protein Engineering | $520,817 | |
| Federal grant· 2 of 3 same day | Department of Health and Human Services · Phase I · Dock and Lock: novel protein engineering | $134,285 | |
| Federal grant· 3 of 3 same day | Department of Health and Human Services · Phase II · Dock and Lock: Novel Protein Engineering | $366,809 | |
| Federal grant· 1 of 3 same day | Department of Health and Human Services · Phase II · MAb-based targeted chemotherapy of lung cancer | $239,702 | |
| Federal grant· 2 of 3 same day | Department of Health and Human Services · Phase II · MAb-based targeted chemotherapy of lung cancer | $724,653 | |
| Federal grant· 3 of 3 same day | Department of Health and Human Services · Phase I · MAb-based targeted chemotherapy of lung cancer | $114,334 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel RNase-based Immunotoxin for CD74-positive B-cell Malignancies | $134,285 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy | $133,835 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Combined radio- and immunotherapy of aggressive NHL | $1,137,221 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Combined radio- and immunotherapy of aggressive NHL | $859,792 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · F-18 Labeled Peptides for Pretargeted PET Imaging of Pancreatic Cancer | $605,718 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · F-18 Labeled Peptides for Pretargeted PET Imaging of Pancreatic Cancer | $517,243 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel multivalent/multifunctional agents derived from a humanized anti-insulin-li | $192,688 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy | $2,283,892 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy | $544,981 | |
| Federal grant | Department of Health and Human Services · Phase I · Use of milatuzumab in modulating graft vs. host disease | $191,143 | |
| Federal grant | Department of Health and Human Services · Phase I · Humanized Anti-Trop2-SN-38 Conjugate For Advanced Pancreatic Cancer | $227,025 | |
| Federal grant | Department of Health and Human Services · Phase I · Bispecific antibody pretargeted immunoPET of prostate cancer | $276,833 | |
| Federal grant | Department of Health and Human Services · Phase I · Localization of Pancreatic Cancer by a Pretargeted 18F-Hapten-Peptide | $213,982 | |
| Federal grant | Department of Health and Human Services · Phase I · TROP-2-targeted tetrameric ranpirnase for therapy of triple-negative breast cance | $200,782 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1302 | Azalea Therapeutics | — | — |
| 1303 | Maze Therapeutics | — | — |
| 1304 | LUNG THERAPEUTICS INC | — | — |
| 1305 | Immunomedics | — | — |
| 1306 | INVENIO THERAPEUTICS INC | — | — |
| 1307 | CONFOMETRX, INC. | — | — |
| 1308 | Cavatar LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Dosages Of Immunoconjugates Of Antibodies And SN-38 For Improved Efficacy And Decreased Toxicityapplication
- Neoadjuvant Use Of Antibody-drug Conjugatesapplication
- Antibody-drug Conjugates And Uses Thereofapplication
- Dosages Of Immunoconjugates Of Antibodies And SN-38 For Improved Efficacy And Decreased Toxicityapplication
- Dosages Of Immunoconjugates Of Antibodies And SN-38 For Improved Efficacy And Decreased Toxicitygranted
- Antibody-drug Conjugates And Uses Thereofgranted
- Dosages Of Immunoconjugates Of Antibodies And SN-38 For Improved Efficacy And Decreased Toxicitygranted
- Efficacy Of ANTI-TROP-2-SN-38 Antibody Drug Conjugates For Therapy Of Tumors Relapsed/refractory To Checkpoint Inhibitorsapplication
- Efficacy Of ANTI-TROP-2-SN-38 Antibody Drug Conjugates For Therapy Of Tumors Relapsed/refractory To Checkpoint Inhibitorsapplication
- Efficacy Of ANTI-TROP-2-SN-38 Antibody Drug Conjugates For Therapy Of Tumors Relapsed/refractory To Checkpoint Inhibitorsapplication
- Efficacy Of ANTI-TROP-2-SN-38 Antibody Drug Conjugates For Therapy Of Tumors Relapsed/refractory To Checkpoint Inhibitorsapplication
- Therapy For Metastatic Urothelial Cancer With The Antibody-drug Conjugate, Sacituzumab Govitecan (IMMU-132)application
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.